General Information of the Compound
Compound ID
CP0039413
Compound Name
CEP-1347
    Show/Hide
Synonyms
AC1L31ZX
CEP1347
DB05403
SCHEMBL1649555
ZINC103589452
    Show/Hide
Structure
Formula
C33H33N3O5S2
Molecular Weight
615.777
Canonical SMILES
CCSCc1ccc2n3[C@H]4C[C@](O)(C(=O)OC)[C@](C)(O4)n4c5ccc(CSCC)cc5c5c6CNC(=O)c6c(c2c1)c3c45
    Show/Hide
InChI
InChI=1S/C33H33N3O5S2/c1-5-42-15-17-7-9-22-19(11-17)26-27-21(14-34-30(27)37)25-20-12-18(16-43-6-2)8-10-23(20)36-29(25)28(26)35(22)24-13-33(39,31(38)40-4)32(36,3)41-24/h7-12,24,39H,5-6,13-16H2,1-4H3,(H,34,37)/t24-,32+,33+/m1/s1
    Show/Hide
InChIKey
SCMLRESZJCKCTC-KMYQRJGFSA-N
CAS
156177-65-0
Physicochemical Property
logP
6.1613
Rotatable Bonds
7
Heavy Atom Count
43
Polar Areas
94.72
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
9
Complexity
43

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 9917013
SID: 14936433
ChEMBL ID
CHEMBL290352
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01968, Mitogen-activated protein kinase kinase kinase 9
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000011 CHO Cricetulus griseus (Chinese hamster)  1
1
IC50 = 72 nM
   TI
   LI
   LO
   TS
Biochemical Assays
1 IC50 < 1 nM
2 IC50 = 38 nM
Cell Viability or Cytotoxicity Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000004 SH-SY5Y Homo sapiens (Human)  1
1
IC50 = 5.3 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( CEP1347 )
Drug Name CEP1347
Indication
Asthma
Phase 2/3
Target(s)
Mixed lineage kinase 1 (MAP3K9)
Inhibitor